These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
484 related articles for article (PubMed ID: 17975158)
1. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Lang SA; Moser C; Gaumann A; Klein D; Glockzin G; Popp FC; Dahlke MH; Piso P; Schlitt HJ; Geissler EK; Stoeltzing O Clin Cancer Res; 2007 Nov; 13(21):6459-68. PubMed ID: 17975158 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505 [TBL] [Abstract][Full Text] [Related]
3. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Stoeltzing O; Liu W; Reinmuth N; Fan F; Parikh AA; Bucana CD; Evans DB; Semenza GL; Ellis LM Am J Pathol; 2003 Sep; 163(3):1001-11. PubMed ID: 12937141 [TBL] [Abstract][Full Text] [Related]
4. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model. Nam S; Kim H; Hong D; Park JB; Kim SJ Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812 [TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. Han JY; Oh SH; Morgillo F; Myers JN; Kim E; Hong WK; Lee HY J Natl Cancer Inst; 2005 Sep; 97(17):1272-86. PubMed ID: 16145048 [TBL] [Abstract][Full Text] [Related]
6. HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer. Ghadban T; Dibbern JL; Reeh M; Miro JT; Tsui TY; Wellner U; Izbicki JR; Güngör C; Vashist YK Apoptosis; 2017 Mar; 22(3):369-380. PubMed ID: 27878398 [TBL] [Abstract][Full Text] [Related]
7. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Moser C; Lang SA; Kainz S; Gaumann A; Fichtner-Feigl S; Koehl GE; Schlitt HJ; Geissler EK; Stoeltzing O Mol Cancer Ther; 2007 Nov; 6(11):2868-78. PubMed ID: 18025273 [TBL] [Abstract][Full Text] [Related]
8. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Koga F; Tsutsumi S; Neckers LM Cell Cycle; 2007 Jun; 6(11):1393-402. PubMed ID: 17525527 [TBL] [Abstract][Full Text] [Related]
9. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function. Li Y; Zhang T; Schwartz SJ; Sun D Nutr Cancer; 2011; 63(7):1151-9. PubMed ID: 21875325 [TBL] [Abstract][Full Text] [Related]
10. HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells. Adachi S; Yasuda I; Nakashima M; Yamauchi T; Yamauchi J; Natsume H; Moriwaki H; Kozawa O Oncol Rep; 2010 Jun; 23(6):1709-14. PubMed ID: 20428829 [TBL] [Abstract][Full Text] [Related]
11. Thymoquinone affects hypoxia-inducible factor-1α expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways. Zhao ZX; Li S; Liu LX World J Gastroenterol; 2024 Jun; 30(21):2793-2816. PubMed ID: 38899332 [TBL] [Abstract][Full Text] [Related]
12. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo. Zhang PC; Liu X; Li MM; Ma YY; Sun HT; Tian XY; Wang Y; Liu M; Fu LS; Wang YF; Chen HY; Liu Z Biochem Pharmacol; 2020 Feb; 172():113771. PubMed ID: 31863779 [TBL] [Abstract][Full Text] [Related]
13. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. Moser C; Lang SA; Mori A; Hellerbrand C; Schlitt HJ; Geissler EK; Fogler WE; Stoeltzing O BMC Cancer; 2008 Jul; 8():206. PubMed ID: 18651980 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of Heat Shock Protein 90 suppresses TWIST1 Transcription. Chong KY; Kang M; Garofalo F; Ueno D; Liang H; Cady S; Madarikan O; Pitruzzello N; Tsai CH; Hartwich TMP; Shuch BM; Yang-Hartwich Y Mol Pharmacol; 2019 Aug; 96(2):168-179. PubMed ID: 31175180 [TBL] [Abstract][Full Text] [Related]
15. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines. Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615 [TBL] [Abstract][Full Text] [Related]
16. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors. Ibrahim NO; Hahn T; Franke C; Stiehl DP; Wirthner R; Wenger RH; Katschinski DM Cancer Res; 2005 Dec; 65(23):11094-100. PubMed ID: 16322259 [TBL] [Abstract][Full Text] [Related]
17. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Wang S; Pashtan I; Tsutsumi S; Xu W; Neckers L Cell Cycle; 2009 Jul; 8(13):2050-6. PubMed ID: 19502802 [TBL] [Abstract][Full Text] [Related]
18. LB-1 Exerts Antitumor Activity in Pancreatic Cancer by Inhibiting HIF-1α and Stat3 Signaling. Niu F; Li Y; Lai FF; Ni L; Ji M; Jin J; Yang HZ; Wang C; Zhang DM; Chen XG J Cell Physiol; 2015 Sep; 230(9):2212-23. PubMed ID: 25655308 [TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3. Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I; Taliaferro-Smith L; Diaz R; El-Rayes BF Angiogenesis; 2013 Oct; 16(4):903-17. PubMed ID: 23838996 [TBL] [Abstract][Full Text] [Related]
20. Antimyeloma activity of heat shock protein-90 inhibition. Mitsiades CS; Mitsiades NS; McMullan CJ; Poulaki V; Kung AL; Davies FE; Morgan G; Akiyama M; Shringarpure R; Munshi NC; Richardson PG; Hideshima T; Chauhan D; Gu X; Bailey C; Joseph M; Libermann TA; Rosen NS; Anderson KC Blood; 2006 Feb; 107(3):1092-100. PubMed ID: 16234364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]